Significant Advances and Collaborations Among Viva's Portfolio Companies
TechnoDerma Completes Series A+ Funding
TechnoDerma Medicines Inc., an innovation-oriented R&D biotech company focusing on dermatological diseases, announced the completion of its Series A+ funding round, securing tens of millions of RMB. This funding round was supported by the Chengdu Biological City No.1 Equity Investment Fund Partnership and Chengdu Hi Tech Investment Development, highlighting the capital market's recognition of TechnoDerma's clinical assets for Androgenetic Alopecia (AGA) and Atopic Dermatitis (AD).
- TDM-105795, a topical drug for AGA, completed Phase I clinical trials in December 2022 and is expected to commence Phase II trials by mid-March 2023.
- TDM-180935, targeting AD, received FDA approval for Phase I clinical trials in August 2022 and has officially entered this phase in the United States.
Genhouse Bio Recognized in Healthcare Venture 50
Genhouse Bio, dedicated to transforming cancer treatment with next-generation small-molecule therapeutics, was listed in the "2022 Healthcare Venture 50 in the Investment Industry". This recognition underscores Genhouse's innovation capability and R&D strength, following its completion of several hundred million RMB Series B financing in 2022.
- The company has established four new drug R&D centers and is advancing its core products, GH35 (KRAS G12C inhibitor) and GH21 (SHP2 inhibitor), in clinical trials.
- GH55, an ERK inhibitor, has obtained clinical approval in the United States and completed the first patient dosing in Phase I clinical trials in China.
AIxplorerBio's New Headquarters and Cooperation Agreement
AIxplorerBio celebrated the relocation of its new headquarters in Xiuzhou district, Jiaxing, and signed a cooperation agreement with Xiuzhou National High-tech Zone. This agreement aims to foster the development of innovative drugs in autoimmune and neurodegenerative diseases, leveraging the integration of drug research and AI.
QureBio's Q-1801 Project Approved by CDE
QureBio announced that its Q-1801 project, a bispecific antibody targeting SIRPα and PD-L1, received clinical trial approval from China's CDE on January 11, 2023. This marks QureBio's second clinical application project and its fourth IND approval from China and the United States.
VivaVision and Everads Collaborate on Retinal Disease Therapies
VivaVision is partnering with Everads Therapy to develop safer, more effective, and durable treatments for retinal diseases. The collaboration will utilize Everads' suprachoroidal drug delivery technology to develop certain molecules from VivaVision.
Arthrosi's Positive Phase 2b Results for AR882
Arthrosi Therapeutics announced positive topline results from its Phase 2b clinical study of AR882 for chronic gout treatment, paving the way for Phase 3 clinical development.
Triumvira Immunologics and Merck Collaboration
Triumvira Immunologics has entered a clinical trial collaboration with Merck to evaluate the combination of TAC01-HER2 cell therapy and KEYTRUDA® (pembrolizumab) in treating HER2-positive solid tumors, highlighting the potential of combining novel T cell therapeutics with anti-PD-1 therapy.